Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming 37th SITC annual meeting to be held November 8-12 2022 (Boston, MA & virtual).

20 October 2022

37th SITC annual meeting 2022
20 October 2022

Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming 37th SITC annual meeting to be held November 8-12 2022 (Boston, MA & virtual).
[ Read more ]
3 June 2022

PRESS RELEASE – IPH5201 (CD39 mAb) to advance into Phase 2
3 June 2022

– PRESS RELEASE – For immediate release Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer   Lyon, France, June 6th, 2022 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, provides an update on its CD39 program: Innate Pharma announced that IPH5201, the CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, will advance into a Phase 2 clinical trial in lung cancer. About IPH5201 antibody IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech commenced the CD39 program at its inception in 2010, then entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). Jeremy Bastid, Chief Executive Officer of OREGA Biotech, commented “We are very pleased that IPH5201 antibody is now progressing into a Phase 2 trial; this represents a major achievement for our company. Our academic cofounders are also very proud of having been involved in the discovery of the immunoregulatory role of the adenosine pathway in cancer, the components of which are now being targeted in multiple clinical trials”. Download the Press Release. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President. Contact Jeremy Bastid, Chief Executive Officer Tel.: +33 (0)4 37 49 87 20 jeremy.bastid@orega-biotech.com   For more information: www.orega-biotech.com
[ Read more ]
4 April 2022

AACR annual meeting 2022
4 April 2022

Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 9-13 in New Orleans, Louisiana.
[ Read more ]
4 February 2022

World Cancer Day
4 February 2022

Today marks World Cancer Day 2022. With 10 million deaths per year, cancer is the second leading cause of death in the world. At OREGA Biotech we are committed to discover and develop novel cancer immunotherapies. We thank our collaborators and partners with whom we work hard to achieve this goal !
[ Read more ]